You are here

Change in Grade Low Grade Side Effects in ph+CML cp patients after switching therapy from IM to NIL

Paper:3782 'Change in Chronic Low-Grade Non-hematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)'

Jorge E. Cortes, MD1, Jeffrey H. Lipton, MD, PhD2, Carole B. Miller, MD3*, Sikander Ailawadhi, MD4, Luke Akard, MD5, Javier Pinilla-Ibarz, MD, PhD6*, Felice P. Lin, PharmD7*, Solveig G. Ericson, MD, PhD7 and Michael J. Mauro, MD8

Cortes, MD1, Jeffrey H. Lipton, MD, PhD2, Carole B. Miller, MD3*, Sikander Ailawadhi, MD4, Luke Akard, MD5, Javier Pinilla-Ibarz, MD, PhD6*, Felice P. Lin, PharmD7*, Solveig G. Ericson, MD, PhD7 and Michael J. Mauro, MD8

Background:A large number of Ph+ CML pts treated with IM experience mild to moderate AEs that can negatively impact QoL. A recent study (Efficace F et al. Ann Hematol. 2012) reported that pts and healthcare professionals ranked several AEs induced by BCR-ABL tyrosine kinase inhibitors (fatigue ranked first) in the top 10 issues that adversely impact QoL in pts. The primary objective of the ongoing ENRICH study is to evaluate improvement of IM-related chronic low-grade non-hematologic AEs at the end of cycle (EOC) 3 (ie, after 12 weeks) in CML-CP pts when switched from IM to NIL because of chronic low-grade AEs.
This is a report on 45 evaluable pts who completed EOC 3 as of the data cut-off (6/1/2012).

Conclusions: The majority of IM-related non-hematologic AEs improved within 3 mo after switching to NIL; nearly half of the AEs resolved by EOC 1. More than half of pts experienced improvement in QoL and symptom burden on NIL. In general, pts achieved deeper molecular responses on study and approximately a quarter of pts reached MR4.5 after the switch to nilotinib.

Read full report here:


https://ash.confex.com/ash/2012/webprogram/Paper53738.html